PK
Peter Kaiser
Chief Development Officer

Peter Kaiser insider trades: Ocular Therapeutix (OCUL) stock sales

Chief Development Officer, Ocular Therapeutix Last trade Oct 2, 2026 12 Form 4 filings
$187K
Sold, last 12 months
5 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2024
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Peter reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Oct 2, 2026OCUL↓ Sell$70K
Aug 24, 2026OCUL↓ Sell$33K
May 26, 2026OCUL↓ Sell$24K
Feb 23, 2026OCUL↓ Sell$23K
Nov 24, 2025OCUL↓ Sell$36K
Oct 2, 2025OCUL↓ Sell$106K
Aug 25, 2025OCUL↓ Sell$36K
May 23, 2025OCUL↓ Sell$21K
Feb 24, 2025OCUL↓ Sell$21K
Nov 25, 2024OCUL↓ Sell$26K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other OCUL insiders

Open-market trades in the last 12 months

About Peter Kaiser's insider trades

Peter Kaiser is Chief Development Officer at Ocular Therapeutix (OCUL). Since Nov 25, 2024, Peter has reported no open-market purchases and 10 sales worth $398K on SEC Form 4. In the last 12 months: 5 sales ($187K).

Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OCUL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.